RINVOQ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). RINVOQ may be used as monotherapy or in combination with MTX or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
One pill once a day1*
RINVOQ is a 15 mg extended-release pill. For RA, RINVOQ may be used as monotherapy or in combination with MTX or other nonbiologic DMARDs.
- Tablet can be taken at any time of day, but at about the same time each day
- Tablets should be swallowed whole, and should not be split, crushed, or chewed
- Can be taken with or without food
- Store between 2 and 25°C in the original bottle in order to protect from moisture. Keep out of reach and sight of children
* Please see Product Monograph for complete dosing and administration information.
Download the Dosing Booklet to get started
DMARD: disease-modifying antirheumatic drug; MTX: methotrexate.
The RINVOQ bottle was awarded the Arthritis Society Ease-of-Use Commendation, due to its: 2,3*
- Easy-to-grip shape and texture
- Embedded tool that helps puncture the foil liner to simplify medication access
* The Arthritis Society Ease-of-Use commendation recognizes products that have been independently tested with people living with arthritis and is not intended as a general product endorsement. The Ease-of-Use logo indicates the ease of use only and does not endorse the therapeutic properties of the product.
Click here for additional information and for a link to the Product Monograph discussing:
- The most serious warnings and precautions regarding serious infections, malignancies, thrombosis and major adverse cardiovascular events.
- Other relevant warnings and precautions regarding lipid parameters; gastrointestinal perforations; hematologic events; liver enzyme elevation; hypersensitivity reactions; patients with severe hepatic impairment; concomitant use with other potent immunosuppressants, biologic DMARDs, or other Janus kinase (JAK) inhibitors; immunizations; viral reactivation, including herpes (e.g. herpes zoster) and hepatitis B; malignancies, including NMSC; increases in creatine phosphokinase; monitoring and laboratory tests; pregnant women; reproductive health; breast-feeding; geriatrics (≥65 years of age); pediatrics (<18 years of age); Asian patients.
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.
References
1. RINVOQ Product Monograph. AbbVie Corporation.
2. Data on file. AbbVie Corporation.
3. Intuitive Design. AbbVie Child Resistant Special Feature Closure Packaging Evaluation Report of Consumer Product Accessibility for Users with Arthritis. October 2017.
